Pharmacogenomics-guided personalized medicine in a clinical setting: real-world data.

ABSTRACT:

Background

Pharmacogenetic testing plays a key role in personalized pharmacotherapy and improving treatment outcomes; however, its benefit in clinical hyperpolypharmacy (≥ 10 chronic drugs) remains uncertain.

Objective

This study assessed the impact of extensive pharmacogenetic testing in hyperpolypharmacy patients. The primary outcome was the number of actionable drug-gene interactions (DGIs) per patient; secondary outcomes included clinical recommendations, clinician adherence, and DGIs with potential for severe adverse events.

Design

This intervention included 100 hyperpolypharmacy inpatients (≥ 10 drugs) from Maasstad Hospital internal ward and Antes psychiatry ward. Eligible patients (≥ 18 years) underwent a 14-gene pharmacogenetic panel test. A multidisciplinary

SUBMITTER: Liang J 

PROVIDER: S-EPMC12846737 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature